- Lexaria’s patented DehydraTECH technology proved effective for sildenafil delivery in animal study PDE5-A21-1
- The company also made some notable strides with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD
- By doing so, it hopes to capitalize on the growing cardiovascular drugs market, which is projected to be valued at $107.8 billion by 2025 (https://cnw.fm/8bk1Y)
- With the success of its studies thus far, the company seeks to conduct even more trials over the 2022 calendar year
Lexaria Bioscience (NASDAQ: LEXX) has, since its inception, remained committed to enhancing the speed and efficiency of orally-delivered fat-soluble active molecules and drugs. Through its patented DehydraTECH(TM) drug delivery technology that began development in 2014, the company is offering potential solutions for conditions including, but not limited to hypertension, smoking cessation, anti-viral treatments, and other drug classes.
In what has marked a landmark achievement for Lexaria, its DehydraTECH technology proved effective for sildenafil delivery in an animal study conducted on lab rats. In addition, the study demonstrated that this technology offered improved treatment of erectile dysfunction, a condition that, according to estimates, will affect about 322 million men worldwide by 2025 (https://cnw.fm/NFBJK).
When compared to the most common sildenafil product- Viagra, Lexaria’s alternative proved to be more effective, with a delivery of 74% more sildenafil into the bloodstream on average than the concentration-matched, generic control formulation. For reference, Viagra is only moderately bioavailable orally at about 40%, with most people citing its slowness to act as a primary complaint.
Lexaria has also made incredible developments with its HYPER-H21-4 clinical study on hypertension and heart disease treatment using DehydraTECH-CBD. Given the success of previous studies, the company also announced plans for more trials over the year 2022.
“During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018!” noted Chris Bunka, the Chief Executive Officer (“CEO”) of Lexaria.
“We have conducted studies across broad areas of interest but also concentrated in specific areas where we have had supportive data,” he added (https://cnw.fm/lFJIa).
For 2022, the company is focusing on DehydraTECH-processed-CBD for potential heart disease and hypertension treatment. Mr. Bunka also noted that from April (or sooner), the company should kick off what it terms as its largest-ever hypertension study.
“If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022,” noted Mr. Bunka.
These strides stamp Lexaria’s position as a global innovator in drug delivery platforms. But, more importantly, they seek to create value for shareholders while also positioning the company for growth as time progresses. Lexaria looks to capitalize on this growth and is, therefore, investing heavily into its R&D to introduce new treatments and receive regulatory approval for existing ones.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.canadiancannabiswire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire is part of the InvestorBrandNetwork.